Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 2/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 5/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737266 | 0.96 | SORT1 (0.37) | SORT1GRNACACBACACAUBE2N | |
| SCHEMBL30737243 | 0.94 | SORT1 (0.43) | SORT1GRNACACBACACAUBE2N | |
| SCHEMBL30737188 | 0.86 | SORT1 (0.47) | SORT1GRNLMNAMAPTKMT2A | |
| SCHEMBL30737430 | 0.81 | YAP1 (0.45) | SORT1GRNACACBACACALMNA | |
| SCHEMBL30737217 | 0.81 | SORT1 (0.43) | SORT1GRNACACBACACALMNA | |
| SCHEMBL30737357 | 0.80 | SORT1 (0.45) | SORT1GRNLMNAMAPTKMT2A | |
| SCHEMBL30737180 | 0.80 | SORT1 (0.46) | SORT1GRNLMNAMAPTKMT2A | |
| SCHEMBL30737240 | 0.80 | SORT1 (0.47) | SORT1GRNLMNAMAPTKMT2A | |
| SCHEMBL30737487 | 0.79 | SORT1 (0.49) | SORT1GRNKMT2ALIPE | |
| SCHEMBL31646330 | 0.77 | SORT1 (0.53) | SORT1GRNKMT2ALIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | SORT1 1/4885GRN 842/4885ACACB 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.